Recurrence Patterns and Second Primary Lung Cancers After Stereotactic Body Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer: Implications for Surveillance

Micro-Abstract The optimal surveillance regimen remains unclear for patients treated with stereotactic body radiation therapy (SBRT) for early-stage non–small-cell lung cancer (SCLC). We assessed 366 patients with early-stage NSCLC treated with SBRT. In patients with progression after SBRT, 84% of c...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2016-05, Vol.17 (3), p.177-183.e2
Main Authors: Spratt, Daniel E, Wu, Abraham J, Adeseye, Victoria, Din, Shaun U, Shaikh, Fauzia, Woo, Kaitlin M, Zhang, Zhigang, Foster, Amanda, Rosenzweig, Kenneth E, Gewanter, Richard, Huang, James, Rimner, Andreas
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung - epidemiology
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - radiotherapy
Computed tomography
Early stage
Female
Follow-Up Studies
Hematology, Oncology and Palliative Medicine
Humans
Incidence
Lung - diagnostic imaging
Lung Neoplasms - epidemiology
Lung Neoplasms - pathology
Lung Neoplasms - radiotherapy
Male
Middle Aged
Neoplasm Staging
Neoplasms, Second Primary - epidemiology
Neoplasms, Second Primary - pathology
Neoplasms, Second Primary - radiotherapy
Non–small-cell lung cancer
Pulmonary/Respiratory
Radiosurgery
Retrospective Studies
Stereotactic body radiation therapy (SBRT)
Surveillance
Tomography, X-Ray Computed
Treatment Outcome
United States - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract The optimal surveillance regimen remains unclear for patients treated with stereotactic body radiation therapy (SBRT) for early-stage non–small-cell lung cancer (SCLC). We assessed 366 patients with early-stage NSCLC treated with SBRT. In patients with progression after SBRT, 84% of cases occurred within the first 2 years. In patients who experienced second primary lung cancers, 33% of cases occurred after 2 years. Close monitoring beyond 2 years may be necessary in patients treated with SBRT.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2015.09.006